A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
OBJECTIVES: Outer membrane vesicle (OMV) vaccines are used against outbreaks of capsular group B Neisseria meningitidis (MenB) caused by strains expressing particular PorA outer membrane proteins (OMPs). Ferric enterobactin receptor (FetA) is another variable OMP that induces type-specific bacterici...
| Auteurs principaux: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
Elsevier
2015
|